93789-69-6

Usage

Uses

Used in Pharmaceutical Industry:
6β-Hydroxy 21-Acetyloxy Budesonide is used as an anti-inflammatory agent for its ability to reduce inflammation and alleviate symptoms associated with various conditions. As a metabolite of Budesonide, it plays a crucial role in the body's response to inflammation and helps in managing the effects of corticosteroid medications.
Used in Research and Development:
6β-Hydroxy 21-Acetyloxy Budesonide is utilized in research and development for studying the metabolism and pharmacological effects of Budesonide. This helps in understanding the compound's role in treating inflammation and developing new therapeutic agents with improved efficacy and safety profiles.
Used in Drug Formulation:
6β-Hydroxy 21-Acetyloxy Budesonide is used in the formulation of various drug products, such as creams, ointments, and inhalers, to deliver the anti-inflammatory effects of Budesonide to the target site. This ensures optimal therapeutic outcomes and minimizes potential side effects associated with systemic administration.

Upstream product

• 51333-05-2 (22R)-21-acetoxy-11β-hydroxy-16α,17α-propylmethylenedioxypregna-1,4-diene-3,20-dione 

Relevant academic research and scientific papers

Synthesis and structure elucidation of potential 6-oxygenatedated metabolites of (22R)-6*9α-difluoro-11β,21-dihydroxy-16α,17α-propylmethylenedioxypregn-4 -ene-3,20-dione, and related glucocorticosteroids

(22R)-6α,9α-Difluoro-11β,21-dihydroxy-16α,17α-propylmethylenedioxypregn- 4-ene-3,20-dione (rofleponide) is a synthetic glucocorticosteroid with high affinity for the rat thymus glucocorticoid receptor and a very high biotransformation rate demonstrated through incubation with a human liver S9 subcellular fraction. Because oxidation in the 6-position is an important metabolic pathway of glucocorticosteroids, the potential 6β-hydroxy and 6-oxo metabolites of rofleponide were synthesized to be used as reference compounds. Three alternative routes were used to reach the 6-hydroxy compound: (a) a one-step procedure involving allylic oxidation of rofleponide by selenium dioxide, (b) selenium dioxide oxidation of the corresponding 1,4-diene followed by selective 1,2-hydrogenation using Wilkinson's catalyst, and (c) autoxidation of a 3-methoxypregna-3,5-diene derivative. All three routes proceeded stereospecifically. Routes (a) and (c) gave approximately the same overall yield of the 6β-hydroxy epimer, whereas the overall yield from route (b) was much lower, primarily because of incomplete 1,2-hydrogenation. The 6-oxo compound was prepared through Pfitzner/Moffat oxidation of the 6-hydroxy compound. The stereochemistry of the 6-hydroxy substituent is discussed on the basis of 1H-NMR spectroscopy and supplementary 2D NOESY experiments. Copyright (C) 2000 Elsevier Science Inc.